“VOMITING IS A POTENTIAL ADVERSE DRUG REACTION FOR LEVOMILNACIPRAN”. International Journal of Pharmaceutical Sciences and Drug Research 9, no. 5 (September 1, 2017): 224–227. Accessed April 30, 2026. https://ijpsdronline.com/index.php/journal/article/view/562.